143 related articles for article (PubMed ID: 33256400)
21. Metformin exerts multitarget antileukemia activity in JAK2
Machado-Neto JA; Fenerich BA; Scopim-Ribeiro R; Eide CA; Coelho-Silva JL; Dechandt CRP; Fernandes JC; Rodrigues Alves APN; Scheucher PS; Simões BP; Alberici LC; de Figueiredo Pontes LL; Tognon CE; Druker BJ; Rego EM; Traina F
Cell Death Dis; 2018 Feb; 9(3):311. PubMed ID: 29472557
[TBL] [Abstract][Full Text] [Related]
22. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.
Baffert F; Régnier CH; De Pover A; Pissot-Soldermann C; Tavares GA; Blasco F; Brueggen J; Chène P; Drueckes P; Erdmann D; Furet P; Gerspacher M; Lang M; Ledieu D; Nolan L; Ruetz S; Trappe J; Vangrevelinghe E; Wartmann M; Wyder L; Hofmann F; Radimerski T
Mol Cancer Ther; 2010 Jul; 9(7):1945-55. PubMed ID: 20587663
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors.
Wang T; Liu X; Hao M; Qiao J; Ju C; Xue L; Zhang C
Bioorg Med Chem Lett; 2016 Jun; 26(12):2936-2941. PubMed ID: 27130359
[TBL] [Abstract][Full Text] [Related]
24. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
25. Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation.
Liu KL; Li XY; Wang DP; Xue WH; Qian XH; Li YH; Lin QQ; Li S; Meng FH
J Med Chem; 2021 Sep; 64(18):13356-13372. PubMed ID: 34473510
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2.
Wang W; Diao Y; Li W; Luo Y; Yang T; Zhao Y; Qi T; Xu F; Ma X; Ge H; Liang Y; Zhao Z; Liang X; Wang R; Zhu L; Li H; Xu Y
Bioorg Med Chem Lett; 2019 Jun; 29(12):1507-1513. PubMed ID: 30981578
[TBL] [Abstract][Full Text] [Related]
27. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
Forsyth T; Kearney PC; Kim BG; Johnson HW; Aay N; Arcalas A; Brown DS; Chan V; Chen J; Du H; Epshteyn S; Galan AA; Huynh TP; Ibrahim MA; Kane B; Koltun ES; Mann G; Meyr LE; Lee MS; Lewis GL; Noguchi RT; Pack M; Ridgway BH; Shi X; Takeuchi CS; Zu P; Leahy JW; Nuss JM; Aoyama R; Engst S; Gendreau SB; Kassees R; Li J; Lin SH; Martini JF; Stout T; Tong P; Woolfrey J; Zhang W; Yu P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7653-8. PubMed ID: 23127890
[TBL] [Abstract][Full Text] [Related]
28. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-
Wu Y; Wang B; Wang J; Qi S; Zou F; Qi Z; Liu F; Liu Q; Chen C; Hu C; Hu Z; Wang A; Wang L; Wang W; Ren T; Cai Y; Bai M; Liu Q; Liu J
J Med Chem; 2019 Jul; 62(13):6083-6101. PubMed ID: 31250638
[TBL] [Abstract][Full Text] [Related]
29. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).
Burns CJ; Bourke DG; Andrau L; Bu X; Charman SA; Donohue AC; Fantino E; Farrugia M; Feutrill JT; Joffe M; Kling MR; Kurek M; Nero TL; Nguyen T; Palmer JT; Phillips I; Shackleford DM; Sikanyika H; Styles M; Su S; Treutlein H; Zeng J; Wilks AF
Bioorg Med Chem Lett; 2009 Oct; 19(20):5887-92. PubMed ID: 19762238
[TBL] [Abstract][Full Text] [Related]
30. Discovery, Optimization, and Structure-Activity Relationship Study of Novel and Potent RSK4 Inhibitors as Promising Agents for the Treatment of Esophageal Squamous Cell Carcinoma.
Yuan Y; Xu J; Jiang L; Yu K; Ge Y; Li M; He H; Niu Q; Shi X; Fan L; Chen Z; Zhao Z; Li S; Xu Y; Wang Z; Li H
J Med Chem; 2021 Sep; 64(18):13572-13587. PubMed ID: 34496560
[TBL] [Abstract][Full Text] [Related]
31. Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer.
Li Y; Yang G; Zhang J; Tang P; Yang C; Wang G; Chen J; Liu J; Zhang L; Ouyang L
J Med Chem; 2021 Aug; 64(16):12022-12048. PubMed ID: 34351741
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors.
Chen H; Li R; Ning X; Zhao X; Jin Y; Yin Y
Eur J Med Chem; 2019 Sep; 178():141-153. PubMed ID: 31177074
[TBL] [Abstract][Full Text] [Related]
33. Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors.
Wang Y; Huang W; Xin M; Chen P; Gui L; Zhao X; Tang F; Wang J; Liu F
Bioorg Med Chem; 2017 Jan; 25(1):75-83. PubMed ID: 27771180
[TBL] [Abstract][Full Text] [Related]
34. Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy.
Chen Y; Yuan X; Zhang W; Tang M; Zheng L; Wang F; Yan W; Yang S; Wei Y; He J; Chen L
J Med Chem; 2019 Feb; 62(3):1577-1592. PubMed ID: 30629434
[TBL] [Abstract][Full Text] [Related]
35. Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway.
Ioannidis S; Lamb ML; Wang T; Almeida L; Block MH; Davies AM; Peng B; Su M; Zhang HJ; Hoffmann E; Rivard C; Green I; Howard T; Pollard H; Read J; Alimzhanov M; Bebernitz G; Bell K; Ye M; Huszar D; Zinda M
J Med Chem; 2011 Jan; 54(1):262-76. PubMed ID: 21138246
[TBL] [Abstract][Full Text] [Related]
36. Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.
Ma X; Diao Y; Ge H; Xu F; Zhu L; Zhao Z; Li H
Bioorg Med Chem Lett; 2020 Apr; 30(8):127048. PubMed ID: 32122740
[TBL] [Abstract][Full Text] [Related]
37. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
38. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors.
Zhang H; Jing L; Liu M; Goto M; Lai F; Liu X; Sheng L; Yang Y; Yang Y; Li Y; Chen X; Lee KH; Xiao Z
Eur J Med Chem; 2021 Nov; 223():113634. PubMed ID: 34147745
[TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
Chu-Farseeva YY; Mustafa N; Poulsen A; Tan EC; Yen JJY; Chng WJ; Dymock BW
Eur J Med Chem; 2018 Oct; 158():593-619. PubMed ID: 30243158
[TBL] [Abstract][Full Text] [Related]
40. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
